| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic rhinitis. CysLT1 receptor is sensitive to the CysLT1 receptor antagonist currently used to treat allergic rhinitis and asthma. Recent studies have begun to uncover receptors selective for LTE4: GPR99. To clarify the expression of GPR99 receptor in human nasal mucosa, we investigated immunohistochemical localization of GPR99 receptor in human nasal mucosa, and intracellular calcium influx in vitro. The immunohistochemical study revealed that vascular smooth muscle and vascular endothelial cells showed intense immunoreactivity for GPR99 receptor. LTE4 caused a rapid increase of the intracellular Ca2+ concentration. Both CysLT1 and CysLT2 receptor antagonists did not affect the LTE4-induced intracellular Ca2+ response. These results suggest that a potential third CysLT receptor such as GPR80/99 receptor may contribute LTE4-induced activation of nasal vascular cells.
|
